Lessons from acute HIV infection.

PURPOSE OF REVIEW Understanding the characteristics of transmission during acute HIV infection (AHI) may inform targets for vaccine-induced immune interdiction. Individuals treated in AHI with a small HIV reservoir size may be ideal candidates for therapeutic HIV vaccines aiming for HIV remission (i.e. viremic control after treatment interruption). RECENT FINDINGS The AHI period is brief and peak viremia predicts a viral set point that occurs 4-5 weeks following infection. Robust HIV-specific CD8 T-cell responses lower viral set points. Phylogenetic analyses of founder viruses demonstrated unique bottleneck selections and specific genetic signatures to optimize for high-fitness variants and successful transmission events. HIV clades, route of transmission and the presence of minor variants may affect vaccine protection. Antiretroviral treatment in AHI results in smaller HIV reservoir size, better CD4 T-cell recovery and fewer virus escapes. SUMMARY The knowledge of untreated and treated AHI informs the development of vaccines, in that preventive vaccines will require broad coverage for multiple clades and antigenic variants associated with unique bottleneck selections. Vaccines that help the host to control viremia could minimize onward transmission. Therapeutic HIV vaccines aimed at HIV remission should be studied in early-treated individuals who have few or no viral escape mutants and a more preserved immune system.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0.

[1]  P. Kaleebu,et al.  Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection , 2016, Journal of acquired immune deficiency syndromes.

[2]  Richard Jefferys,et al.  International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.

[3]  J. Angel,et al.  HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine , 2016, Expert Opinion on Biological Therapy.

[4]  Jerome H. Kim,et al.  Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. , 2016, The New England journal of medicine.

[5]  Sergei L. Kosakovsky Pond,et al.  Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus , 2016, PLoS pathogens.

[6]  J. Carlson,et al.  HIV-1–Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection , 2016, The Journal of Immunology.

[7]  M. Lederman,et al.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.

[8]  J. Montaner,et al.  Programmatic Implications of Acute and Early HIV Infection. , 2015, The Journal of infectious diseases.

[9]  A. Fomsgaard,et al.  Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells , 2015, PloS one.

[10]  K. Shekhar,et al.  Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. , 2015, Immunity.

[11]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[12]  Jerome H. Kim,et al.  Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection , 2015, AIDS.

[13]  Jessica L. Prince,et al.  Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression , 2015, Proceedings of the National Academy of Sciences.

[14]  Jerome H. Kim,et al.  Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation , 2014, PLoS pathogens.

[15]  Phuc T. Pham,et al.  Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection , 2014 .

[16]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[17]  P. Kaleebu,et al.  Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection , 2014, Journal of the International AIDS Society.

[18]  H. Ding,et al.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha , 2013, Retrovirology.

[19]  Jessica Prince,et al.  Selection bias at the heterosexual HIV-1 transmission bottleneck , 2013, Science.

[20]  Matthew S. Lewis,et al.  Immune clearance of highly pathogenic SIV infection , 2013, Nature.

[21]  G. Carcelain,et al.  Immune interventions in HIV infection , 2013, Immunological reviews.

[22]  W. Miller,et al.  The Detection and Management of Early HIV Infection: A Clinical and Public Health Emergency , 2013, Journal of acquired immune deficiency syndromes.

[23]  Jerome H. Kim,et al.  A novel acute HIV infection staging system based on 4th generation immunoassay , 2013, Retrovirology.

[24]  Feng Gao,et al.  Phenotypic properties of transmitted founder HIV-1 , 2013, Proceedings of the National Academy of Sciences.

[25]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[26]  G. Learn,et al.  Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. , 2013, Virology.

[27]  B. Haynes,et al.  Acute HIV-1 Infection. , 2011, The New England journal of medicine.

[28]  Alan S. Perelson,et al.  High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men , 2010, PLoS pathogens.

[29]  Persephone Borrow,et al.  The immune response during acute HIV-1 infection: clues for vaccine development , 2009, Nature Reviews Immunology.

[30]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[31]  Alan S. Perelson,et al.  The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection , 2009, The Journal of experimental medicine.

[32]  L. Meyer,et al.  Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. , 2009, Blood.

[33]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[34]  F. Hecht,et al.  The Relation Between Symptoms, Viral Load, and Viral Load Set Point in Primary HIV Infection , 2007, Journal of acquired immune deficiency syndromes.

[35]  J. Baeten,et al.  Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[37]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  F. Roudot-thoraval,et al.  The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. , 1998, The Journal of infectious diseases.

[39]  A. De Maria,et al.  Absence of HIV-1 after treatment cessation in an infant. , 2014, The New England journal of medicine.

[40]  J. Mittler,et al.  Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. , 2000, AIDS.